SCHEMBL856556

SCHEMBL856556

O=C(O)NC(Cc1ccccc1)Cc1nc2ncc(Br)cc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
MAPK10 P53779 1/20 0.57
HDAC8 Q9BY41 2/20 0.44
RXFP1 Q9HBX9 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
MAPT P10636 1/20 0.43
ATM Q13315 1/20 0.43
ESR1 P03372 1/20 0.42
PKM P14618 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.40
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39
PIN1 Q13526 1/20 0.39
NOS3 P29474 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4060448 0.78 ALDH1A1 (0.58) ALDH1A1MAPK10RXFP1SMN1; SMN2MEN1
SCHEMBL4051158 0.75 ALDH1A1 (0.57) ALDH1A1MAPK10RXFP1SMN1; SMN2MEN1
SCHEMBL4050337 0.73 ALDH1A1 (0.53) ALDH1A1MAPK10RXFP1SMN1; SMN2MEN1
SCHEMBL4053179 0.72 ALDH1A1 (0.54) ALDH1A1MAPK10HDAC8RXFP1SMN1; SMN2
SCHEMBL3714726 0.72 ALDH1A1 (0.60) ALDH1A1MAPK10RXFP1SMN1; SMN2MEN1
SCHEMBL856558 0.72 ALDH1A1 (0.54) ALDH1A1MAPK10RXFP1SMN1; SMN2MEN1
SCHEMBL1901572 0.71 FPR2 (0.52) MEN1KMT2ANPC1RAB9AMME
SCHEMBL25295806 0.70 HDAC8 (0.41) HDAC8PIN1MME
SCHEMBL25256196 0.70 HDAC8 (0.41) HDAC8PIN1MME
SCHEMBL856557 0.69 ALDH1A1 (0.52) ALDH1A1MAPK10RXFP1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3395/4885MAPK10 244/4885HDAC8 886/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA ALDH1A1 3049/4885MAPK10 206/4885HDAC8 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.